Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
Article content
(690,000 patients annually are diagnosed with metastatic lytic bone lesions with only non-curative, palliative therapies available)
Article content
Article content
ZetaMet™ (Zeta-BC-003) is a first-of-its kind molecular pathway designed to resolve metastatic cancer lesions, inhibit pain, and regenerate bone
Phase 2a study examines the safety and efficacy of ZetaMet™ (Zeta-BC-003) for the treatment of metastatic bone lesions to the spine in Stage 4 breast cancer patients
ZetaMet™ (Zeta-BC-003) has the potential to be a curative treatment, without systemic limitations, for metastatic lytic breast cancer lesions to bone
Article content
SYRACUSE, N.Y. — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic and primary breast cancers, announced today they have successfully completed enrollment in their phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067).
Article content
'We are excited to reach another critical milestone in the development of ZetaMet™ (Zeta-BC-003),' said Joe C. Loy, Zetagen's Chief Executive Officer. 'We launched this study with stage IV breast cancer patients suffering from spinal metastases, because we recognize their severe pain and how debilitating it is, and that current treatments remain largely palliative. Our objective with ZetaMet™ is to eliminate cancer cells responsible for bone destruction, alleviate pain, stimulate the regeneration of bone lost to lytic lesions, enhance overall quality of life, while improving survival rates.'
Article content
The 26-week study, conducted at the University of British Columbia, (UBC) Vancouver, BC, Canada, will evaluate the safety and efficacy of ZetaMet™ (Zeta-BC-003) in treating vertebral bone defects created by lytic metastatic breast cancer. The study will measure the reduction of skeletal related events (SRE), pain, change in vertebral body defect size, and postoperative prescribed opioid use. The Company anticipates reporting top-line results early fourth quarter of 2025.
Article content
Zetagen expects to submit an Investigation New Drug (IND) application to the U.S. Food and Drug Administration ('FDA'), leveraging its FDA's Breakthrough designations.
Article content
ZetaMet™ (Zeta-BC-003) is the first-of-its-kind, synthetic, small-molecule delivered via a proprietary controlled-release carrier intended to resolve metastatic breast cancer bone lesions, administered locoregionally, to inhibit pain while regenerating new bone, with the potential to increase survival rates.
Article content
ZetaMet's (Zeta-BC-003) small molecule mechanism of action (MOA) via a novel molecular pathway initiates a circuit which results in tumor cell death.
Article content
The US Food & Drug Administration (FDA) has recognized Zetagen's discoveries with multiple Breakthrough Designations including ZetaMet™ (Zeta-BC-003).
Article content
Zetagen with FDA and Health Canada (HC) approval via their Expanded Access (Compassionate Use) programs has treated several patients with ZetaMet™ (Zeta-BC-003) with results published in multiple peer-reviewed journals.
Article content
Peer-reviewed 2-year follow up clinical data published in 2023 on ZetaMet™ (Zeta-BC-003) demonstrated resolution of 7 lytic lesions (radiated and non-radiated), reduction in pain, significant reduction in opioid pain medication (4-fold), prevention of vertebral fracture, and increased survival rate in a patient living with Stage 4 breast cancer. To view this publication via open access, go to: https://www.tandfonline.com/doi/full/10.2217/pmt-2023-0069
Article content
Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary breast cancers.
Article content
The company's 'Zeta' platform encompasses the following breast oncological drug candidates ZetaMet™ (Zeta-BC-003), ZetaMAST™ (Zeta-MBC-005) and (NEW) ZetaPrime™ (Zeta-PBC-007). To learn more, visit www.zetagen.com
Article content
Zetagen will attend the upcoming San Antonio Breast Cancer Symposium (SABCS) this December.
Article content
This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
ACEL Power Partners With Vector Náutico to Launch MOLA-e Electric Boat Line in Spain
Article content VANCOUVER, British Columbia & MADRID — ACEL Power, a leader in intelligent electric propulsion systems, is pleased to announce a strategic partnership with Vector Náutico, a respected boat builder based in Madrid. The collaboration introduces MOLA-e powered by ACEL, a new line of eco-conscious electric boats designed for coastal and inland cruising. Article content This partnership marks ACEL Power's official entry into the Spanish market—an important step in its European expansion strategy. As demand for sustainable marine solutions grows across the EU, this alliance underscores both companies' shared commitment to innovation and environmental responsibility. Article content 'We are excited to partner with Vector Náutico, an innovative builder committed to sustainability,' said Natasha Chawla, VP of Sales and Marketing at ACEL Power. 'The MOLA line aligns perfectly with our 50HP and 75HP Intelligent Electric Series, powered by 32 kWh and 43 kWh LFP battery packs. These systems deliver high energy density, extended lifecycle, and enhanced thermal stability—offering zero-emission propulsion without compromising performance.' Article content 'Working with ACEL Power brings our vision for the next generation of electric boats to life,' said Rus Kochman, CEO of Vector Náutico. 'The MOLA-e is elegant, efficient, and built for modern boaters who value reliability and sustainability.' Article content The 5.99-meter MOLA blends the design of a luxury yacht with the accessibility of a day cruiser. Its optimized hull geometry maximizes range and handling, while wide swim platforms offer easy water access—ideal for lake cruising, coastal exploration, and eco-tourism. Article content Available Configurations: Article content Both setups are fully integrated and engineered for quiet, efficient, zero-emission cruising. Article content The first MOLA units will debut in mid-2025, with sea trials and showcase events scheduled throughout Spain. Pricing and customization options will be announced soon. Article content This partnership further accelerates ACEL Power's mission to lead the marine industry's transition to clean, intelligent propulsion—region by region, boat by boat. Article content For more information, visit: About ACEL Power ACEL Power, headquartered in Vancouver, Canada, is a pioneering manufacturer of electric outboard propulsion systems, leading the marine industry in innovation and sustainability. Noted for introducing the world's first mass-produced 50 and 75HP electric motors, ACEL Power is committed to shaping a sustainable future through the creation of a smart electric eco-system. With a forward-looking vision, ACEL aims to offer a comprehensive range from 1HP to 650HP, establishing new benchmarks for marine propulsion in performance, safety, and longevity. Leveraging patented technology and integrated software solutions, ACEL Power is driving change towards a cleaner, more efficient boating experience. Article content About Vector Náutico Article content Article content Article content Article content Article content Contacts Article content Media Inquiries: Article content ACEL Power Inc. Natasha Chawla, VP Sales & Marketing Email: natasha@ Article content
CTV News
2 hours ago
- CTV News
SAAQclic ‘bumpy' as early as 2018, witness tells Gallant commission
The Gallant Commission, tasked with investigating the failures of the Société de l'assurance automobile du Québec (SAAQ) IT transition, on May 15, 2025, in Quebec City. (The Canadian Press/Jacques Boissinot) The digital transition at Quebec's automobile insurance board (SAAQ) was already 'bumpy' in 2018, the commission investigating the SAAQclic fiasco heard Monday. Sylvain Cloutier, director of the project office, testified before the Gallant commission, which travelled to Quebec City to begin its sixth week of hearings. He spoke about the coloured indicators used by his team to track progress — markers that, without clear explanation, often shifted from red to green. 'When things become increasingly chaotic, doesn't accountability matter?' asked Justice Denis Gallant, pressing Cloutier on his apparent lack of control over how the colours were assigned. Cloutier said the indicators 'on their own weren't enough' to give a full picture of the project's status. The board's vice-president of information technology, Karl Malenfant, would regularly step in to offer 'explanations.' Malenfant's name has surfaced repeatedly over the past six weeks at the Gallant commission. 'There were problems, but Mr. Malenfant didn't try to hide them,' said Cloutier. 'He's an experienced man. He's led major projects at Hydro-Québec, at Rio Tinto. He knows what he's talking about. He came in to explain things and reassure the team — not reassure as in spinning stories,' Cloutier added. 'Was everyone aware?' commission lawyer Vincent Ranger asked. 'Was Mr. Malenfant transparent about how difficult the rollout was?' 'Yes,' Cloutier replied. 'Would it be fair to say Mr. Malenfant is naturally optimistic?' Ranger followed up. 'Yes, that's true,' Cloutier said. 'But not in a head-in-the-clouds way. He likes a challenge.' 'I didn't take bribes' Cloutier also admitted Monday to manipulating a public tender worth over $1 million so it would be awarded to external consultant Stéphane Mercier. 'That was my mistake,' Cloutier acknowledged under questioning from Justice Gallant. 'I'm not saying what I did was right. But I take responsibility — it was me.' In 2017, Cloutier urgently requested the bidding threshold be lowered to $990,000 after Mercier informed him he couldn't qualify for the contract because he didn't have authorization from Quebec's financial markets authority. That authorization is required for contracts valued at more than $1 million. 'I was in a panic,' Cloutier said, recalling thinking, 'If I don't have this guy to keep going, we're in deep trouble (…) I'm losing expertise.' 'I did it with the intention of not delaying the project,' he said. 'I didn't take any bribes. I'm not going on fishing trips. I'm not sailing around on a yacht. That's not what this is.' This report by The Canadian Press was first published in French June 9, 2025.
CTV News
3 hours ago
- CTV News
CTV National News: Cruise industry hoping to capitalize on travellers avoiding the U.S.
Paul Hollingsworth explains how Canada's cruise industry in eastern Canada is hoping to benefit from a growing reluctance to travel to the U.S. this season.
